NCT07460674 is a clinical trial in Female Subjects Undergoing Controlled Ovarian Hyperstimulation, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What condition does NCT07460674 study?

NCT07460674 studies Female Subjects Undergoing Controlled Ovarian Hyperstimulation.

Is NCT07460674 still recruiting?

NCT07460674 is currently not yet recruiting. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT07460674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serum FSH Levels During Controlled Ovarian Stimulation

Not yet recruiting Last updated 9 March 2026

What this trial tests

trial in Female Subjects Undergoing Controlled Ovarian Hyperstimulation in 500 participants. Not yet recruiting.

Timeline

16 February 2026

Primary endpoint
1 December 2030

1 December 2030

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	500
Start date	16 February 2026
Primary completion	1 December 2030
Estimated completion	1 December 2030
Sites	1 location across Canada

Conditions studied

Female Subjects Undergoing Controlled Ovarian Hyperstimulation — all drugs for Female Subjects Undergoing Controlled Ovarian Hyperstimulation →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

Adults 18 to 44, female only, with Female Subjects Undergoing Controlled Ovarian Hyperstimulation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

-Trigger day FSH levels
Time frame: 60 months
Serum Follicle-stimulating hormone (FSH) (mIU/mL) measured at the day of the trigger shot
Trigger day E2 levels
Time frame: 60 months
Serum Estradiol (E2) (pg/mL) levels measured at trigger shot day
Number of patients reaching trigger
Time frame: 60 months
The number of patients that received the trigger shot and proceeding to oocyte retrieval / The number pf patients canceled during the ovarian stimulation
Number of oocytes retrieved
Time frame: 60 months
The number of oocytes collected in the oocyte retrieval procedure
Number of transferable embryos
Time frame: 60 months
Number of embryos were transferred in the fresh cycle plus the number of frozen embryos

Sponsor's own description

Follicle-stimulating hormone (FSH) plays a central role in controlled ovarian stimulation (COS) during in vitro fertilization (IVF) cycles. While baseline FSH is commonly used to assess ovarian reserve, the clinical significance of dynamic FSH changes during stimulation remains unclear. Limited evidence suggests that serum FSH levels during COS may reflect ovarian response and could be associated with follicular development and treatment outcomes, yet FSH is not routinely monitored throughout stimulation protocols. This prospective single-center cohort study aims to evaluate the dynamics of serum FSH levels during COS and to examine their association with ovarian response and IVF outcomes. Serum FSH, luteinizing hormone (LH) and estradiol (E2) will be measured at predefined time points during stimulation. Associations between FSH levels and oocyte yield, embryo development, and pregnancy outcomes will be analyzed to better understand the clinical relevance of FSH monitoring during IVF treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07460674 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07460674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing